Active Not Recruiting
OBSERVATIONAL
NCT06596642
A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This real-world study will assess the efficacy and safety of luspatercept treatment for β-thalassemia major in Taiwan as well as the impact on quality of life.
Interventions
Name:
Luspatercept
Type:
DRUG
Description:
As per product label
Primary Outcomes
Measure:
Number of Red Blood Cell (RBC) transfusion units received by participants
TimeFrame:
Baseline, every 3 weeks thereafter until week 96
Description:
Measure:
Participant hemoglobin (Hb) level results
TimeFrame:
Baseline, every 3 weeks thereafter until week 96
Description:
Measure:
Participant serum ferritin results
TimeFrame:
Baseline, week 12, 24, 36, 48, 60, 72, 84 and 96
Description:
Trial Information
NCT ID
NCT06596642
Status
Active Not Recruiting
Study Type
OBSERVATIONAL
Sponsor
Bristol-Myers Squibb
Last Updated
December 15, 2025